AHR and breast carcinoma: However, like other receptors, relatively non-toxic SAhRMs which exhibit tissue-specific AhR agonist or antagonist activities have been developed [47,48] including the AhR-active drug “aminoflavone” which has been in clinical trials for breast cancer [49].